Skip to content Menu
Science Chronicle

Science Chronicle

A Science and Technology Blog

Sidebar
  • Home
  • PODCASTS
  • About
  • ARCHIVES
  • Award for R. Prasad

Category: Gilead Sciences

Posted on October 17, 2020October 17, 2020

WHO supported Solidarity trial finds remdesivir ineffective but WHO prequalifies it anyway

Even as WHO supported Solidarity Therapeutics Trial found remdesivir to be ineffective in reducing mortality and duration of hospital stay, the global body prequalified the drug the same day the…

Continue Reading
Posted on October 16, 2020October 16, 2020

Remdesivir, other repurposed drugs ineffective, says WHO’s Solidarity trial

WHO’s Solidarity Therapeutics Trial, the largest randomised control trial carried out in the world during the pandemic, has found that four repurposed drugs — remdesivir, interferon, hydroxychloroquine and lopinavir/ritonavir regimes…

Continue Reading
Posted on June 23, 2020

Gilead to begin testing inhaled remdesivir for early-stage treatment

Gilead plans to begin a Phase-1 clinical trial in August of an inhaled version of remdesivir for early-stage COVID-19 treatment outside of hospital settings. The drug is currently approved for…

Continue Reading
Posted on May 24, 2020

Remdesivir trial results: NEJM, NIAID and Gilead provide conflicting information

Information shared by the three stakeholders — NEJM, NIAID and Gilead — on critical issues about whether the drug’s ability to reduce mortality is statistically significant and which category of…

Continue Reading
Posted on January 6, 2016December 13, 2017

India rejects patent claims on two HIV/AIDS drugs

The Indian Patent Office (IPO) has rejected applications from two U.S. pharmaceutical companies on grounds of “evergreening”, raising hopes of a further lowering of prices of two life-saving drugs used…

Continue Reading
Follow Science Chronicle on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 10,581 other followers

Archives

Social

  • View Prasad.Ravindranath’s profile on Facebook
  • View @RPrasad12’s profile on Twitter
  • View Prasad.Ravindranath@gmail.com’s profile on Google+

Recent Posts

  • Indian scientists divided over restricted use approval for Covaxin January 15, 2021
  • Vaccine dilemma: To take or not to take Covaxin January 15, 2021
  • Serious violations in Covaxin trial in Bhopal show nothing has changed since the egregious HPV vaccine trial January 13, 2021
  • New challenges in conducting COVID-19 vaccine trials in India January 9, 2021
  • I would not take Covaxin without efficacy data: Gagandeep Kang January 8, 2021

Most Read Posts

  • Vaccine dilemma: To take or not to take Covaxin
  • I would not take Covaxin without efficacy data: Gagandeep Kang
  • Indian scientists divided over restricted use approval for Covaxin
  • Serious violations in Covaxin trial in Bhopal show nothing has changed since the egregious HPV vaccine trial
  • India's TB control programme renamed to reflect its intent on ending TB
  • 'Serum’s pneumococcal vaccine will be available by June 2020'
  • Loosening the vice-like grip of chewing tobacco
  • Home
  • PODCASTS
  • About
  • ARCHIVES
  • Award for R. Prasad
  • Home
  • PODCASTS
  • About
  • ARCHIVES
  • Award for R. Prasad
Create a website or blog at WordPress.com
Top
Follow Science Chronicle on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 10,581 other followers

Archives

Cancel